Kayne Anderson Rudnick Investment Management
CYTK icon

Kayne Anderson Rudnick Investment Management’s Cytokinetics CYTK Stock Holding History

Kayne Anderson Rudnick Investment Management’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-180
Closed -$11.4K – 976
2025
Q4 		$11.4K Hold
180
– – ﹤0.01% 698
2025
Q3 		$9.89K Buy
+180
New +$7.42K ﹤0.01% 715

Other funds holding CYTK

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management's CYTK Position: Q1 2026 in Review

Kayne Anderson Rudnick Investment Management sold out of Cytokinetics (CYTK) in Q1 2026, closing a stake of 180 shares — an estimated $11.4K sold.

Kayne Anderson Rudnick Investment Management first reported a position in CYTK in Q3 2025 and held it in 2 quarters. The position peaked at $11.4K in Q4 2025. 440 funds tracked by Wall St. Rank hold CYTK as of Q1 2026.

  • Kayne Anderson Rudnick Investment Management reported no remaining Cytokinetics position as of Q1 2026 after selling out during the quarter.
  • Kayne Anderson Rudnick Investment Management sold 180 Cytokinetics shares in Q1 2026, an estimated $11.4K.
  • Kayne Anderson Rudnick Investment Management first reported a position in Cytokinetics in Q3 2025 and held it in 2 quarters.
  • Kayne Anderson Rudnick Investment Management's Cytokinetics position peaked at $11.4K in Q4 2025.
  • 440 funds tracked by Wall St. Rank held Cytokinetics as of Q1 2026.

Based on Kayne Anderson Rudnick Investment Management's 13F filing for Q1 2026, filed 14 May 2026.